Moderna #Vaccine safety & efficacy:
overall #Vaccine efficacy against infection with #COVID19 = 94.1% (means a vaccinated person has 94.1% less risk of getting COVID if exposed to the virus)!
This is excellent, but remember in the general population efficacy will a bit
overall #Vaccine efficacy against infection with #COVID19 = 94.1% (means a vaccinated person has 94.1% less risk of getting COVID if exposed to the virus)!
This is excellent, but remember in the general population efficacy will a bit
N.B.: efficacy assessment starts 14 days after 2nd dose
more efficacy date:
against severe disease: (30 in placebo vs. 0 in vaccine)
against death: (1 in placebo, vs. 0 in vaccine)
We’re indebted to those who volunteered for the trial despite the placebo!
more efficacy date:
against severe disease: (30 in placebo vs. 0 in vaccine)
against death: (1 in placebo, vs. 0 in vaccine)
We’re indebted to those who volunteered for the trial despite the placebo!
REALLY cool but preliminary data on against asymptomatic infection and therefore transmission: there appears to be some protection against this, and analysis is ongoing. We should know more soon!
Couple of other important points about efficacy:
the 2nd dose appears to be important as there were 2 severe cases of COVID in participant who only received 1 dose
efficacy is a bit lower in >65yrs than in 18-65yrs old participants
the 2nd dose appears to be important as there were 2 severe cases of COVID in participant who only received 1 dose
efficacy is a bit lower in >65yrs than in 18-65yrs old participants
The study participants were ethnically diverse and efficacy analysis suggests 97.5% again infection for communities of colour.
It also included people considered high risk for severe COVID: chronic lung disease, asthma, cardiac disease, severe obesity, diabetes, HIV, etc.)
It also included people considered high risk for severe COVID: chronic lung disease, asthma, cardiac disease, severe obesity, diabetes, HIV, etc.)
For participants at high risk fo severe COVID, the vaccines seems to be highly against infection, including for those with HIV
Now to safety data:
The most common side effects (due to reactogenicity) are:
Pain at the site of , headache/fever/chills, muscle/body pains, etc.
swollen lymph nodes (most common amongst 18-64 yrs)
All of these side effects resolves in a few days
The most common side effects (due to reactogenicity) are:
Pain at the site of , headache/fever/chills, muscle/body pains, etc.
swollen lymph nodes (most common amongst 18-64 yrs)
All of these side effects resolves in a few days
More safety data:
No anaphylaxis/ hypersensitivity reported
3 temporary facial paralysis (Bell’s palsy) reported: 2 in vaccine group and 1 in placebo
the safety analysis of participants continues long term
I think the FDA will keep a close eye on Bell’s palsy
No anaphylaxis/ hypersensitivity reported
3 temporary facial paralysis (Bell’s palsy) reported: 2 in vaccine group and 1 in placebo
the safety analysis of participants continues long term
I think the FDA will keep a close eye on Bell’s palsy
Because the incidence of Bell’s palsy is low & it occurs in both placebo (basically salt water) & vaccinated group, it’s hard to establish causal relationship with the vaccine. But as I’ve said above, any neurological effects will be monitored closely.
13 pregnancies (6 vaccine group, 7 placebo) occurred at various points during the trial.
They have performed toxicology studies on the pregnant & breastfeeding mothers and have to-date no side effects have been identified. Analysis is on going.
They have performed toxicology studies on the pregnant & breastfeeding mothers and have to-date no side effects have been identified. Analysis is on going.
Overall slide performance for this vaccine! The pain & aches seems a bit more frequent compared to Pfizers, but overall not much difference in terms of performance.
Once again here’s the beautiful graph that helps you visualize what a blessing #vaccines are!
Once again here’s the beautiful graph that helps you visualize what a blessing #vaccines are!
Remember that durability of immunity is under investigation & will take time to establish. The antibody levels of participants will be monitored at various intervals.
Interim data shows at 119 days, it’s holding strong & doing better than disease generated antibodies
Interim data shows at 119 days, it’s holding strong & doing better than disease generated antibodies
Addendum: I wrote this late last night & apologize for all the typos as I rushed to breakdown the info!
in it should say *solid* and not slide
in it should say *solid* and not slide